AURKA is a predictor of chemotherapy response and prognosis for patients with advanced oral squamous cell carcinoma

详细信息    查看全文

• 作者：Yadong Li ; Jinsong Zhang
• 关键词：Aurora kinase A ; Oral squamous cell carcinoma ; Chemotherapy ; Indicator ; Prognosis
• 刊名：Tumor Biology
• 出版年：2015
• 出版时间：May 2015
• 年：2015
• 卷：36
• 期：5
• 页码：3557-3564
• 全文大小：847 KB
• 参考文献：1.Hauswald H, Simon C, Hecht S, Debus J, Lindel K. Long-term outcome and patterns of failure in patients with advanced head and neck cancer. Radiat Oncol. 2011;6:70.View Article PubMed Central PubMed
  2.Choe KS, Haraf DJ, Solanki A, Cohen EE, Seiwert TY, Stenson KM, et al. Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. Cancer. 2011;117:4671-.View Article PubMed
  3.Wang R, Wang JH, Chu XY, Geng HC, Chen LB. Expression of stk15 mRNA in hepatocellular carcinoma and its prognostic significance. Clin Biochem. 2009;42:641-.View Article PubMed
  4.Baba Y, Nosho K, Shima K, Irahara N, Kure S, Toyoda S, et al. Aurora-A expression is independently associated with chromosomal instability in colorectal cancer. Neoplasia. 2009;11:418-5.View Article PubMed Central PubMed
  5.Kiyose S, Nagura K, Tao H, Igarashi H, Yamada H, Goto M, et al. Detection of kinase amplifications in gastric cancer archives using fluorescence in situ hybridization. Pathol Int. 2012;62:477-4.View Article PubMed
  6.Pan JY, Ajani JA, Gu J, Gong Y, Quin A, Hung M, et al. Association of Aurora-A (STK15) kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiation. Cancer. 2012;118:4346-3.View Article PubMed
  7.Denzinger S, Stoehr R, Schwarz S, Eichenseher N, Brockhoff G, Obermann EC, et al. Low level STK15 amplification in histologically benign urothelium of patients with bladder cancer adversely predicts patient outcome following cystectomy. Int J Oncol. 2007;31:793-02.PubMed
  8.Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol. 2003;4:842-4.View Article PubMed
  9.Yang H, He L, Kruk P, Nicosia SV, Cheng JQ. Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int J Cancer. 2006;119:2304-2.View Article PubMed
  10.Katayama H, Wang J, Treekitkarnmongkol W, Kawai H, Sasai K, Zhang H, et al. Aurora kinase-a inactivates DNA damage-induced apoptosis and spindle assembly checkpoint response functions of p73. Cancer Cell. 2012;21:196-11.View Article PubMed Central PubMed
  11.Zeng JY, Sharma S, Zhou YQ, Yao HP, Hu X, Zhang R, et al. Synergistic activities of MET/RON inhibitor BMS-777607 and mTOR inhibitor AZD8055 to polyploid cells derived from pancreatic cancer and cancer stem cells. Mol Cancer Ther. 2014;13:37-8.View Article PubMed
  12.Yao R, Zheng J, Zheng W, Gong Y, Liu W, Xing R. Vx680 suppresses the growth of Hepg2 cells and enhances the chemosensitivity to cisplatin. Oncol Lett. 2014;7:121-.PubMed Central PubMed
  13.Ke CS, Liu HS, Yen CH, Huang GC, Cheng HC, Huang CY et al. Curcumin-induced Aurora-A suppression not only causes mitotic defect and cell cycle arrest but also alters chemosensitivity to anticancer drugs. J Nutritional Biochem 2014
  14.Lee YR, Wu WC, Ji WT, Chen JY, Cheng YP, Chiang MK, et al. Reversine suppresses oral squamous cell carcinoma via cell cycle arrest and concomitantly apoptosis and autophagy. J Biomed Sci. 2012;19:9.View Article PubMed Central PubMed
  15.Tanaka H, Nakashiro K, Iwamoto K, Tokuzen N, Fujita Y, Shirakawa R, et al. Targeting aurora kinase a suppresses the growth of human oral squamous cell carcinoma cells in vitro and in vivo. Oral Oncol. 2013;49:551-.View Article PubMed
  16.Pan C, Yan M, Yao J, Xu J, Long Z, Huang H, et al. Aurora kinase small molecule inhibitor destroys mitotic spindle, suppresses cell growth, and induces apoptosis in oral squamous cancer cells. Oral Oncol. 2008;44:639-5.View Article PubMed
  17.Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-6.View Article PubMed
  18.Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative pcr and the 2(-delta delta c(t)) method. Methods. 2001;25:402-.View Article PubMed
  19.Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, et al. Radiation Therapy Oncology G, Intergroup USA: Long-term results of RTOG trial 8911 (USA intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007;25:3719-5.View Article PubMed
  20.Zhong LP, Zhang CP, Ren GX, Guo W, William Jr WN, Sun J, et al. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol. 2013;31:744-1.View Article PubMed
  21.Sun H, Wang Y, Wang Z, Meng J, Qi Z, Yang G. Aurora-A controls cancer cell ra
• 作者单位：Yadong Li (1)
  Jinsong Zhang (1)
  
  1. Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1, Youyi Road,Yuzhong District, Chongqing, 400016, China
  
• 刊物主题：Cancer Research;
• 出版者：Springer Netherlands
• ISSN：1423-0380

文摘

Increasing evidence proposes the benefits of cisplatin-based chemotherapy in a subpopulation of patients with oral squamous cell carcinoma (OSCC), yet reliable indicators for this subpopulation are poorly explored. AURKA, also known as aurora kinase A, playing important functions in cell mitosis and making cells resistant to cisplatin through dysregulation of DNA damage repair networks, has been reported to be upregulated in OSCC, making AURKA a promising indicator. In this study, we recruited 78 patients with advanced OSCC to examine the expression of AURKA and the correlation with chemotherapy response and clinical outcomes. We found that AURKA was strongly expressed in 31 (39.74?%) of the 78 advanced OSCC samples and its expression was significantly associated with cisplatin resistance (P--.023), clinical recurrence (P--.021), and 5-year survival (P--.019). Chemotherapy increased AURKA expression in post-chemotherapy samples, yet with no significance (P--.101). Multivariate Cox proportional hazards regression model analysis demonstrated that lymph node samples with positive, strong AURKA staining, and poor chemotherapy response were independently associated with the 5-year survival and disease-free survival. Inhibiting AURKA expression in OSCC cell lines remarkably increased their sensitivity to cisplatin treatment by 2.5-fold difference. Our results imply that the overexpression of AURKA in advanced OSCC not only plays a role in the disease course but also shows an involvement in cisplatin treatment response. AURKA level may be a valuable predictor for patients with advanced OSCC, with downregulation of AURKA being a promising adjuvant therapy in this patient population.